ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

FNA Paragon 28 Inc

7.49
0.00 (0.00%)
Pre Market
Last Updated: 12:00:06
Delayed by 15 minutes
Share Name Share Symbol Market Type
Paragon 28 Inc NYSE:FNA NYSE Common Stock
  Price Change % Change Share Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 7.49 2 12:00:06

Paragon 28 To Report Second Quarter Financial Results on August 2, 2023

12/07/2023 9:05pm

Business Wire


Paragon 28 (NYSE:FNA)
Historical Stock Chart


From May 2023 to May 2024

Click Here for more Paragon 28 Charts.

Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the second quarter 2023 after market close on Wednesday, August 2, 2023. The company’s management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time / 2:30 p.m. Mountain Time.

Investors interested in listening to the conference call may do so by dialing (888-330-2446) for domestic callers or (240-789-2732) for international callers, using conference ID: 4439305. Live audio of the webcast will be available on the “Investors” section of the company’s website at: ir.paragon28.com. The webcast will be archived and available for replay for at least 90 days after the event.

About Paragon 28, Inc.

Based in Englewood, Colo., Paragon 28, is a leading medical device company exclusively focused on the foot and ankle orthopedic market and is dedicated to improving patient lives. From the onset, Paragon 28® has provided innovative orthopedic solutions, procedural approaches and instrumentation that cover a wide range of foot and ankle ailments including fracture fixation, forefoot, ankle, progressive collapsing foot deformity (PCFD) or flatfoot, charcot foot and orthobiologics. The company designs products with both the patient and surgeon in mind, with the goal of improving outcomes, reducing ailment recurrence and complication rates, and making the procedures simpler, consistent, and reproducible.

Investor Contact: Matthew Brinckman Senior Vice President, Strategy and Investor Relations Phone: (720) 912-1332 mbrinckman@paragon28.com

1 Year Paragon 28 Chart

1 Year Paragon 28 Chart

1 Month Paragon 28 Chart

1 Month Paragon 28 Chart

Your Recent History

Delayed Upgrade Clock